{"analyses":[{"ciLowerLimit":"1.01","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.29","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.047","paramType":"Odds Ratio (OR)","paramValue":"2.31","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"2.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.51","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"6.03","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"8.8","value":"4.8"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"14.9","value":"9.8"},{"groupId":"OG002","lowerLimit":"17.3","upperLimit":"26.9","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"184"},{"groupId":"OG002","value":"281"}],"units":"Participants"}],"description":"SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets administered orally every day QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally every day QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 participants who had evaluable data for this outcome measure. A Non-responder Imputation (NRI) was applied for participants with missing data at the timepoint due to discontinuation or other intercurrent events.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}